FDA issues a formal safety communication, drug safety alert, or compounding risk alert specifically addressing compounded or at-home ketamine use by March 31, 2027.

The FDA (the US drug regulator) already warned about compounded ketamine in 2023 — meaning ketamine mixed or repackaged by pharmacies outside of normal manufacturing standards. Based on growing evidence of unsafe practices in telehealth ketamine prescribing, a new or updated safety alert is expected by early 2027. This would be the government officially telling the public: this specific form of ketamine use carries real risks.

Split out from a vague 'converging pressure' consensus claim into its single falsifiable component. FDA has precedent (the October 2023 compounded ketamine alert) and the same risk signals — off-protocol telehealth prescribing documented in practice-survey data — are now stronger. The original consensus resolve date of 2026-09-10 was unjustifiably tight for agency timelines; extended to align with the enforcement window. Resolves via a dated communication on FDA.gov naming ketamine in a compounded/at-home/telehealth context; routine label updates do not count.